Audio
IMF Chairman of the Board Dr. Brian G.M. Durie interviews Alexis Stamatis, an internationally renowned novelist, poet, and playwright. Diagnosed with myeloma in 2012, Stamatis applies his writer’s perspective to coping with the disease. He says, “I think that half a century from now, people will…
News Article
SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, has announced that the U.S. Food and Drug…
News Article
On Sunday, May 23, 2021, Lori Klein and Betsy Mencher held the first online cooking class, and it was a huge success! Both of them have a strong connection to the myeloma community and have held successful fundraisers in the past. At the beginning of the year, I was contacted by Lori to let…
Audio
Listen to Multiple Myeloma Patient Deidra Jones Share Her Story
Deidra Jones talks about her myeloma diagnosis, coping with both congestive heart failure and multiple myeloma, undergoing treatment with Velcade and a clinical trial with venetoclax, as well as becoming an IMF Support Group…
News Article
The International Myeloma Foundation (IMF) has begun a multiyear, multidisciplinary initiative, M-Power Charlotte, which is designed to promote the early diagnosis and treatment of myeloma in the Black community. The IMF is working with Atrium Health Levine Cancer Institute’s…
News Article
iStopMM Study: Pioneering Screening for Myeloma’s Precursor, MGUS
The Iceland Screens, Treats, or Prevents Multiple Myeloma study (iStopMM) is the first to evaluate the benefits and harms of screening for MGUS, a precursor to the disease.
80,759…
Audio
Listen to Multiple Myeloma Patient Jeff O'Donnell Share His Story
Jeff O'Donnell talks about his myeloma diagnosis, undergoing an autologous stem cell transplant, alleviating side effects with the use of doctor-prescribed CBD-products, and his treatment with Darzalex Faspro®.
In this Myeloma…
Videos
A Virtual Webinar on How to Optimize and Protect Your Immune System Using a Nutrition Based Approach
Watch this webinar to understand how a healthy diet can help fortify your immune system.
We are all hearing about how critical the immune system is for our overall health. What is the immune…
Videos
Darzalex Faspro Is the Subcutaneous Version of the Drug Darzalex
How Darzalex Faspro can improve the quality of life for patients living with multiple myeloma.
In this video, Dr. Joseph Mikhael (IMF Chief Medical Officer) and Kimberly Noonan, DNP, RN, ANP-BC, AOCN® (a member of IMF's Nurse…
Videos
Myeloma Protein Levels in the Blood and the Amount of Myeloma in the BodyIn this episode, Dr. Brian G.M. Durie discusses how the level of myeloma protein found in the blood corresponds to the amount of myeloma found in the body.The BOTTOM LINE: Discuss your situation with your doctor and…
Audio
Listen to Multiple Myeloma Patient Diane Hunter Share Her Story
Diane Hunter discusses receiving her myeloma diagnosis, disparities in healthcare, and how she has coped during the pandemic.
In April of 2016, Diane went in for her annual checkup with her endocrinologist. While going over her…
Audio
.accordion {
box-sizing: border-box;
display: flex;
font-family: Arial, Helvetica, sans-serif;
overflow: hidden;
width: 100%;
}
.accordion-select {
cursor: pointer;
margin: 0;
opacity: 0;
z-index: 1;
}
.accordion-title {
position: relative…
Event
We are all hearing about how critical the immune system is for our overall health. What is the immune system and how can we protect it? Can nutrition improve your immune system for better defense against diseases, bacteria, or viruses? Can supplements help?
Join us to get answers to these…
Page
ABECMA® (idecabtagene vicleucel, also known as “ide-cel”) is the first-in-class B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell immunotherapy approved by the U.S. Food and Drug Administration (FDA) in March 2021 for the treatment of adult patients with relapsed…
Support Group
Videos
How the Immune System Can Be Used To Fight MyelomaIMF Chief Medical Officer Dr. Joseph Mikhael discusses how the immune system can be used to fight multiple myeloma.In particular, he explains that BCMA is found on the surface of myeloma cells and thus makes an excellent target for treatment.…
News Article
LOS ANGELES, CA, April 6, 2021— Amid the pandemic, the team at the International Myeloma Foundation remained steadfast about its goals: Myeloma Action Month (MAM) in March 2021 would inspire the myeloma community and beyond to take action and create awareness about this incurable…
Page
Visit DARZALEX® (daratumumab) for more information about this drug’s original formulation and its intravenous (IV, into the vein) administration. What Is Darzalex Faspro?Darzalex Faspro® is a newer formulation of Darzalex that is administered as an…
Page
What Is Blenrep?Blenrep® (belantamab mafodotin-blmf) is an antibody-drug conjugate (ADC), the first in a new class of treatments for myeloma. Blenrep is the combination of a monoclonal antibody (mAb) that binds to a specific receptor on the surface of myeloma cells called B-cell maturation antigen…
Audio
The “A Day in the Life” podcast from the International Myeloma Foundation features messages of hope and resilience for myeloma patients, caregivers, and their loved ones. This episode features an interview with Jack Aiello, a 26-year multiple myeloma survivor, father of 3, and grandfather of four.…
News Article
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the European Commission (EC) has granted conditional marketing authorization for NEXPOVIO (selinexor), the Company's first-in-class, oral Selective Inhibitor…
News Article
Los Angeles, CA, March 26, 2021—Calling it "a win for patients," the International Myeloma Foundation (IMF) welcomed…
Event
The International Myeloma Foundation will co-host a session at the 8th Annual Eurasian Hematology Oncology Virtual Summit on April 17-18, 2021.
This event is open for registration to healthcare professionals in the myeloma community, however, it is not open to the general public…
Event
Last year, to celebrate my 60th birthday, Huckleberry (an Australian Cattle dog of strong character and questionable intelligence) and I began hiking the Appalachian Trail to raise money for two great causes, The International Myeloma Foundation and The CCHS…
Videos
A Virtual Myeloma Workshop On Disparities in Myeloma Care and Survival
Learn about multiple myeloma, a disease more than twice as common in people of African descent as in whites.
This M-Power Charlotte virtual myeloma workshop includes…
Page
Multiple myeloma can impact your immune system, making you vulnerable to infections. But there is potential for your immune system to fight back. Immunotherapy offers a way to strengthen your defenses and target myeloma cells. By boosting your body's natural defenses, these therapies provide a…
Event
This International Myeloma Foundation Regional Community Workshop is a virtual workshop, set in an engaging environment, that offers myeloma patients and caregivers up-to-the-minute information about multiple myeloma. Topics include an introduction to myeloma (Myeloma 101), upfront treatments at…
Event
This International Myeloma Foundation Regional Community Workshop is a virtual workshop, set in an engaging environment that offers myeloma patients and caregivers up-to-the- minute information about multiple myeloma. Topics include an introduction to myeloma (Myeloma 101…
Event
My mother, Josephine Speller, was diagnosed with multiple myeloma on September 23, 2019 and on November 7, 2019 she transitioned. This was her second battle with MM, and unfortunately, she did not win this battle. My mom loved jewelry, beautiful jewelry, and she introduced me to the love of jewelry…
Event
Register now for a free, interactive online workshop, Saturday, March 20, to learn about multiple myeloma, a disease more than twice as common in people of African descent as in whites. From “Myeloma for Patients Who Are Just Getting Started” to the latest in treatments and research, this…
News Article
Los Angeles, CA, March 11, 2021 –The International Myeloma Foundation (IMF) today launched a multiyear, multidisciplinary initiative called “M-Power Charlotte,” designed to empower people to change the course of myeloma by removing barriers to early diagnosis and treatment in the…
News Article
As part of the mission of International Women’s Day, the International Myeloma Foundation celebrates the achievements of women. In particular, the IMF recognizes the achievements of the organization’s President, Founder, and CEO Susie Durie.
Along with her late husband Brian Novis, Susie founded…
Videos
A Virtual Webinar on How Myeloma Patients Can Build Resilience During the COVID-19 Pandemic
A Coaching Approach to Building Personal Resilience.
In this special virtual presentation, IMF Chairman of the Board Dr. Brian G.M. Durie and Dr. Susan Dunnett, a Senior Lecturer at the University of…
News Article
NORTH HOLLYWOOD, CA, February 25, 2021—Spearheaded by the International Myeloma Foundation, Myeloma Action Month takes place every March to encourage individuals and groups to take actions that positively impact the myeloma community. This year the IMF invites you to join the…
Page
The IMF has partnered with myINTERACT to centralise all your go-to resources and news from the IMF, local support groups, and treatment providers. Learn more about the app here so you never miss a thing.
IMF Person
A Los Angeles native, with the IMF for over 5 years. Work in both the Accounting and Distribution departments doing a variety of tasks. Assist with financial analysis, payables, invoices and many other financial operations to ensure all details and activities have been accounted for and allocated…
Event
On Thursday, February 25, 2021, the IMF will host a FREE “Living Well with Myeloma” Webinar on “Building Your Resilience During Challenging Times," Featured speakers are IMF Chairman of the Board Dr. Brian G.M. Durie and Dr. Susan Dunnett, a Senior Lecturer at the University of Edinburgh in…
News Article
The Scandinavian island’s unique combination of genetic homogeneity, genealogical tradition, and high participation in research make it a prime location for discovery and validation of drug targets.
When patients test as having borderline high-risk smoldering myeloma, should they receive treatment?
Videos
Should borderline high-risk smoldering myeloma patients receive treatment? Dr. Brian G.M. Durie discusses if patients with borderline high-risk smoldering myeloma should start treatment early.The BOTTOM LINE: Monitor your myeloma-levels closely. Discuss your options carefully with your…
Page
The latest updates and information on COVID-19 for myeloma patients: Vaccines, boosters, anti-viral treatments, and answers to FAQs
Event
Dr. Brian G.M. Durie discusses key takeaways from the annual conference and explains how this new and important information relates to myeloma patients, caregivers, and other members of the myeloma community.
…
News Article
The U.S. Food and Drug Administration (FDA) has approved XPOVIO® (selinexor), a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine, in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one…
News Article
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the initiation of a rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (…
News Article
On December 11, 2020, the National Comprehensive Cancer Network® (NCCN) added three different XPOVIO® (selinexor) combination regimens to its Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for previously treated multiple myeloma. Click here to learn more.
Videos
Should myeloma patients adjust their treatment plan?
Dr. Brian G.M. Durie discusses the options available to myeloma patients who have a low level of myeloma protein detectable, and if this means patients should alter their treatment regimen.
The BOTTOM LINE:
If a low…
Videos
What is the purpose of this study?
The aim of the study is to evaluate AMG 701, a BiTE® molecule binding BCMA on MM cells and CD3 on T cells, in RR MM (Amgen, NCT03287908); primary objective was to evaluate safety and tolerability and estimate a biologically active dose;…